Baricitinib compared with placebo for polymyalgia rheumatica
Tests baricitinib with short steroid treatment in adults with polymyalgia rheumatica.
Key facts
- Who runs it
- Centre Hospitalier Regional Et Universitaire De Brest
- Where
- France22 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 140 people, planned
- Started
- 18 Dec 2025
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional
- Record updated
- 19 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 or older with polymyalgia rheumatica (PMR), newly diagnosed or not responding to treatment. It compares baricitinib with placebo, both given with a short course of steroids.
- Age
- At least 50 years old.
- Sex
- All sexes can join.
- Disease stage
- PMR that meets the ACR/EULAR classification criteria, either newly diagnosed or resistant to treatment. Disease activity score PMR-AS-CRP must be above 17. No other inflammatory joint disease, connective tissue disease or vasculitis (inflamed blood vessels).
- Earlier treatment
- For at least 15 days before the start, either no steroids (GCs) or steroids below 15 mg/day. People taking probenecid cannot join.
- Biomarker or test result
- PMR-AS-CRP score above 17.
Main reasons for not taking part
- Signs of giant cell arteritis.
- Cancer in the last 5 years (3 years for some removed skin or cervical cancers).
- Active uncontrolled infection, or uncontrolled high blood pressure or heart disease.
- Blood clot (VTE) within 12 weeks before the start, or more than 1 clot in the past.
- Current smokers older than 65 years.
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- At least 50 years of age
- Fulfilling ACR/EULAR classification criteria for PMR newly diagnosed or treatment resistant
- No GCs or GCs <15 mg/day since at least 15 days prior to planned randomization
- PMR-AS-CRP >17
- Absence of other inflammatory arthropathy, connective tissue diseases or vasculitis
- Able to give informed consent
- French health insurance holder
Who cannot take part
- High risk of VTE because of a history of VTE (DVT and/or PE) within 12 weeks prior to randomization or a history of recurrent (>1) VTE (counting co-occurring DVT+PE as 1 single event)
- History of malignant neoplasm within the last 5 years (or 3 years in case of cervical carcinoma, basal cell or squamous epithelial skin cancer resected with no evidence of recurrence or metastatic disease)
- Current active uncontrolled infection
- Uncontrolled high blood pressure or cardiovascular disease
- Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR
- Planned major surgical procedure during the study or medical history, blood abnormalities or any clinical condition that compromises inclusion
- Alkaline phosphatase (ALP) ≥2 x ULN
- Total bilirubin level (TBL) ≥1.5 x ULN
- Neutropenia (absolute neutrophil count <1000 cells/uL) (<1.00 x 103/uL or <1.00 GI/L)
- Lymphopenia (lymphocyte count <500 cells/uL) (<0.50 x 103/uL or <0.50 GI/L)
- Detailed exclusion criteria related to prior or concomitant therapy, general safety and laboratory data are reported in the protocol
- Current smoker if age >65 years
- Clinical evidence of giant cell arteritis
- Treatment by probenecid
- Patient under court protection or protected adults
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To demonstrate the ability of baricitinib 4 mg plus short GCs treatment in comparison to placebo plus short GCs treatment to obtain a disease activity [PMR-AS-CRP] lower or equal to 10 without oral GCs (prednisone or prednisolone) at week 24 in PMR patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
- Plain-language title
- Baricitinib compared with placebo for polymyalgia rheumaticaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 19 June 2026